How much is a share of SVA biotech worth?
One share of SVA stock can currently be purchased for approximately $6.47. How much money does Sinovac Biotech make? Sinovac Biotech has a market capitalization of $642.41 million and generates $510.62 million in revenue each year.
What is Sinovac Biotech's stock price?
What is Sinovac Biotech's stock price today? One share of SVA stock can currently be purchased for approximately $6.47. How much money does Sinovac Biotech make? Sinovac Biotech has a market capitalization of $642.41 million and generates $510.62 million in revenue each year.
What does svau stand for?
United States SVA Overview Stock Screener Earnings Calendar Sectors Nasdaq Search Ticker SVAU.S.: Nasdaq Sinovac Biotech Ltd. WatchlistCreateSVAAlert
Why is Sava stock slumping in 2022?
SAVA stock ran up more than 1,000% at one point last year on hopes of an imminent breakthrough in the treatment of Alzheimer’s. However, that euphoria has given way in 2022. Increasing concerns around the clinical data for the drug and various scientific study retractions have caused SAVA stock to slump.
When will Sinovac Biotech release its earnings?
Sinovac Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 27th 2021. View our earnings forecast for Sinovac Biotech.
What is the P/E ratio of Sinovac Biotech?
The P/E ratio of Sinovac Biotech is 6.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.90.
What is Sinovac Biotech?
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Is there enough data for Sinovac Biotech?
There is not enough analysis data for Sinovac Biotech.
Does Sinovac pay dividends?
Sinovac Biotech does not currently pay a dividend.
What is Sinovac Biotech?
Sinovac Biotech Ltd is a biopharmaceutical company. The company primarily focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases.
What is market cap?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.
Does market cap include convertible securities?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Why is cassava stock so high in 2021?
Cassava's stock has skyrocketed because the company has a new approach to Alzheimer's treatment.
What is fair value in accounting?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Did the SEC investigate Cassava?
The report comes just two days after Cassava, in an SEC filing, revealed that “certain government agencies” had asked the Company for documentation. It wasn’t clear which agencies were inquiring or what information they sought , and Cassava did say that the requests weren’t accusations of wrongdoin
Is Cassava Sciences a stock?
Cassava Sciences, one of best-performing U.S. stocks this year, has denied claims that it manipulated research results.
What is dividend percentage?
A company's dividend expressed as a percentage of its current stock price.
Does SVA pay dividends?
SVA is not currently paying a regular dividend.
What is Sinovac Biotech?
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company’s product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Where is Sinovac Biotech located?
Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
What is Sinovac Biotech?
Sinovac Biotech Ltd is a biopharmaceutical company. The company primarily focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state and local levels. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets.
What is Morningstar quantitative rating?
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Does Morningstar cover ratings?
Companies with ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
